Table 1.
Physicochemical and biological properties of complexes 1 and 2.
Figure 1.
Synthesis of the salan ligands and titanium salan complexes.
The halo-salan ligands L1 and L2 were synthesised via a Mannich-condensation of the respective phenol, formaldehyde and N,N'-ethylenediamine. The ligands were then metallated with Ti(OiPr)4 in toluene to give complexes 1 and 2.
Figure 2.
Viability of C3 cells after incubation for 48 h with complexes 1 and 2.
Dose-response curves were obtained using an AlamarBlue assay. Measuring the fluorescence and comparison to a negative control gave the relative amount of cells surviving the treatment. The shown dose-effect curves result from three independent test series done in four replicates.
Table 2.
IC50-values of titanium salan complex 1 in Breast-, Colon-, and CNS human cancer cell lines.
Table 3.
IC50-values of titanium salan complex 1 in Melanoma-, Lung-, and Renal human cancer cell lines.
Table 4.
IC50-values of titanium salan complex 1 in Ovarian-, Leukemia-, and Prostate human cancer cell lines.
Table 5.
Growth of established C3 tumors in C57BL/6 mice after treatment with titanium salan complexes 1, 2.
Table 6.
Growth of established C3 tumors in C57BL/6 mice after treatment with titanium salan complexes 1, 2.